New treatment regimen shows clinical benefit in advanced colon cancer

Treatment was beneficial despite resistance to all standard therapeutic approaches

2011-05-19

(Press-News.org) Washington, D.C. -- A new treatment regimen for patients with metastatic colon cancer appears to offer clinical benefit even when used after multiple other treatments have failed, say research physicians at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center.

The research team found that combining a PARP inhibitor with chemotherapy (temozolomide) offers significant benefit in patients who had no further treatment options. However, the study is small, and does not include a comparison arm, so further investigation is needed, they add. The study will be presented in an oral session on Saturday, June 4th, at the 2011 annual meeting of the American Society of Clinical Oncology in Chicago.

PARP, short for "poly (ADP-ribose) polymerase" is a key part of a cell's DNA repair apparatus, and is important for protecting our normal cells against DNA damage. However, cancer cells become resistant to chemotherapy in part by increasing PARP expression and thus rapidly repairing DNA damage intentionally caused by chemotherapy. PARP inhibitors are designed to overcome a cancer cell's ability to repair the damaged DNA. (They are showing promise in both breast and ovarian cancers, and are being studied in a variety of other cancer types).

In this clinical study, doctors administered a potent DNA-damaging chemotherapy, temozolomide, with a PARP inhibitor called ABT-888. The theory is that ABT-888 will diminish the ability of these cancer cells to fix the damage that was just inflicted by the temozolomide, pushing the cancer into a death spiral.

"This is a classic one-two punch: the chemotherapy damages the cancer cells and the PARP inhibitor prevents it from fixing itself, leaving the cell to die," says lead author, Michael Pishvaian, M.D., Ph.D., an assistant professor at Georgetown Lombardi.

This single-arm, phase II study enrolled 49 patients with metastatic disease who were not eligible for surgery and had exhausted all of the standard therapies currently used. Despite having advanced cancer, all study participants were still active at work or home. Researchers found the drug combination controlled cancer growth for nearly six months in 23 percent of the patients, with two patients having a significant reduction in their tumor burden (partial response).

Pishvaian explains, "The treatment was extremely well tolerated, so to have a period of six months with no tumor growth, but also no significant side effects was really meaningful for the patients."

In addition, researchers were able to collect samples of the patients' tumors for further molecular analysis. "By testing tissue samples and identifying their molecular fingerprints, perhaps we can identify which patient subgroups are most likely to respond to this new therapeutic combination," concludes Pishvaian.

### Funding for this study was provided by the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. Abbott provided the study drugs at no charge. Pishvaian reports no personal financial interests related to the study.

About Georgetown Lombardi Comprehensive Cancer Center Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.

About Georgetown University Medical Center Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2009-2010, GUMC accounted for nearly 80 percent of Georgetown University's extramural research funding.

ELSE PRESS RELEASES FROM THIS DATE:

Heart drugs ineffective in treating pulmonary arterial hypertension

2011-05-19

ATS 2011, DENVER – Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health (NIH)-funded study conducted at four U.S. medical centers. This was the first NIH-funded randomized clinical trial (RCT) in PAH. The results of the study will be presented at the ATS 2011 International Conference in Denver. PAH is a progressive, incurable disease characterized by increased blood pressure in the arteries of the ...

Maternal smoking causes changes in fetal DNA

2011-05-19

ATS 2011, DENVER - Children whose mothers or grandmothers smoked during pregnancy are at increased risk of asthma in childhood, but the underlying causes of this are not well understood. Now a new study indicates changes in a process called DNA methylation that occurs before birth may be a root cause. The study will be presented at the ATS 2011 International Conference. DNA methylation is a process that can alter a gene's usual function. These altered genes can be passed along from parent to child. In this case, researchers observed DNA methylation-related changes ...

Standing up to fight

2011-05-19

SALT LAKE CITY, May 18, 2011 – A University of Utah study shows that men hit harder when they stand on two legs than when they are on all fours, and when hitting downward rather than upward, giving tall, upright males a fighting advantage. This may help explain why our ape-like human ancestors began walking upright and why women tend to prefer tall men. "The results of this study are consistent with the hypothesis that our ancestors adopted bipedal posture so that males would be better at beating and killing each other when competing for females," says David Carrier, ...

UCSF team discovers key to fighting drug-resistant leukemia

2011-05-19

Doctors who treat children with the most common form of childhood cancer – acute lymphoblastic leukemia – are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern cancer drugs. Now a team of scientists led by researchers at the University of California, San Francisco have uncovered the basis for this drug resistance: BCL6, a protein that leukemia cells use to stay alive. Targeting this protein may be the key to fighting drug-resistant leukemia, a discovery that may make cancer drugs more powerful and help doctors formulate ...

Auto Recyclers Seek EPA Retraction of Stormwater Permit Guidance Memorandum

2011-05-19

Today, the Automotive Recyclers Association (ARA) urged the Environmental Protection Agency (EPA) to retract its November, 2010 Guidance Memorandum that encourages state permitting authorities to measure industrial stormwater discharges through numeric effluent limits rather than use the traditional and effective best management practices (BMP) approach. "This Memorandum goes well beyond simply updating a policy as EPA suggests," says ARA's CEO Michael E. Wilson. "Rather, it appears to represent a major shift in how best to measure stormwater discharges - ...

The Earth's core is melting ... and freezing

2011-05-19

The inner core of the Earth is simultaneously melting and freezing due to circulation of heat in the overlying rocky mantle, according to new research from the University of Leeds, UC San Diego and the Indian Institute of Technology. The findings, published tomorrow in Nature, could help us understand how the inner core formed and how the outer core acts as a 'geodynamo', which generates the planet's magnetic field. "The origins of Earth's magnetic field remain a mystery to scientists," said study co-author Dr Jon Mound from the University of Leeds. "We can't go and ...

HeliScopeCAGE: A new gene expression analysis technique on a single molecule sequencer

2011-05-19

A new gene expression technique adapted for single molecule sequencing has enabled researchers at the RIKEN Omics Science Center (OSC) to accurately and quantitatively measure gene expression levels using only 100 nanograms of total RNA. The technique, which pairs RIKEN's Cap Analysis of Gene Expression (CAGE) protocol with the Helicos® Genetic Analysis System developed by Helicos BioSciences Corporation, opens the door to the detailed analysis of gene expression networks and rare cell populations. In recent years, next-generation DNA sequencers have produced an increasingly ...

Breaking News! 2011 Urologist Report Reveals "Traction Beats Surgery for Permanent Lengthening of the Male Sex Organ"

2011-05-19

Penile enlargement is one of the most controversial topics today. Many physicians claim that there is no medical proof that the non-surgical methods for increasing the penile size actually work. In addition to that, there are many people online abusing this topic, which is one of the main reasons why everyone is so skeptic about it. With the growing popularity of the penile extenders, one of the most reputable medical journals BJUI (British Journal of Urology International), which is issued as the official journal of the British Association of Urological Surgeons, have ...

Scottish data highlight dangerous practice in pediatric paracetamol prescribing

2011-05-19

Many of the prescriptions issued by GPs for paracetamol either give less than recommended doses to older children or exceed recommended doses in young children. Under-dosing may result in insufficient pain relief and over-dosing can damage a person's liver. "Getting the dose right can become even more complicated when parents also give their children additional paracetamol that they have bought over the counter," says James McLay, a senior member of the research team who studied this issue. The findings are published in the British Journal of Clinical Pharmacology. Paracetamol ...

'Critical baby step' taken for spying life on a molecular scale

2011-05-19

The ability to image single biological molecules in a living cell is something that has long eluded researchers; however, a novel technique, using the structure of diamond, may well be able to do this and potentially provide a tool for diagnosing, and eventually developing a treatment for, hard-to-cure diseases such as cancer. In a study published today, Thursday, 19 May, in the Institute of Physics and the German Physical Society's New Journal of Physics, researchers have developed a technique, exploiting a specific defect in the lattice structure of diamond, to externally ...

Patients of an online obesity clinic achieved the same weight loss as those in clinical trials of semaglutide – but with much lower doses of the drug

Protein bars enriched with collagen have potential as a weight-loss aid, Spanish study finds

Semaglutide may provide early protection against heart disease in high-risk patients—even before clinically meaningful weight loss and prior to the full target dose

New treatment regimen shows clinical benefit in advanced colon cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: